Advertisement

Future Avenues of Translational Care for Patients with Temporomandibular Joint Disorders

  • Francesco ChiappelliEmail author
  • André Barkhordarian
  • Eliseo B. SabalJr
  • Allen Khakshooy
  • G. Gary Demerjian
Chapter

Abstract

This chapter discusses the need for novel avenues and methodologies of fundamental and clinical research of translational healthcare for new and improved treatment of patients with TMD. It discusses certain aspects of current osteoarthritis and chondropathogenesis research, including the promising novel avenues of microRNA and genomic engineering research. The chapter discusses the extent to which these new approaches may improve the diagnosis and treatment and prognosis of patients with TMD in the next decades, with an emphasis on novel individual patient data research and analysis protocols and interpretation. Limitations and fallacies as currently entertained in the field are examined.

Abbreviations

CRSWBCT

Cluster randomized stepped wedge blinded controlled trial

IPR&A

Individual patient research and analysis

miRNA

MicroRNA

RANKL

Receptor activator of nuclear factor κB ligand

STAT3

Signal transducer and activator of transcription 3

TLRs

Toll-like receptors

TMD

Temporomandibular joint disorders

TMJ

Temporomandibular joint

References

  1. 1.
    Alomar X, Medrano J, Cabratosa J, Clavero JA, Lorente M, Serra I, Monill JM, Salvador A. Anatomy of the temporomandibular joint. Semin Ultrasound CT MR. 2007;28:170–83.CrossRefGoogle Scholar
  2. 2.
    AHRQ. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF: Rockville, MD; 2014.Google Scholar
  3. 3.
    Chiappelli F. Fundamentals of evidence-based health care and translational science. Heidelberg: Springer; 2014.CrossRefGoogle Scholar
  4. 4.
    Chiappelli F. Methods, fallacies and implications of comparative effectiveness research (CER) for healthcare in the 21st century. In: Chiappelli F, editor. Comparative effectiveness research (CER): new methods, challenges and health implications. Hauppauge, NY: NovaScience; 2016. Chapter 1.Google Scholar
  5. 5.
    Hickam D, Totten A, Berg A, Rader K, PCORI Methodol Com. PCORI methodology report. Washington, DC: PCORI; 2013.Google Scholar
  6. 6.
    Demerjian GG, Barkhordarian A, Chiappelli F. Testing patient targeted therapies in patients with temporomandibular joint disorder with the arthrokinetic reflex: individual patient research. J Transl Med. 2016;14(1):231.CrossRefGoogle Scholar
  7. 7.
    Chiappelli F. Osteoimmunopathology: evidence-based perspectives from molecular biology to systems biology. New York: Springer; 2011.CrossRefGoogle Scholar
  8. 8.
    Qi Z, Liu W, Lu J. The mechanisms underlying the beneficial effects of exercise on bone remodeling: roles of bone-derived cytokines and microRNAs. Prog Biophys Mol Biol. 2016;122(2):131–9.CrossRefGoogle Scholar
  9. 9.
    Brennan-Speranza TC, Conigrave AD. Osteocalcin: an osteoblast-derived polypeptide hormone that modulates whole body energy metabolism. Calcif Tissue Int. 2015;96(1):1–10.CrossRefGoogle Scholar
  10. 10.
    Li J, Zhang H, Yang C, Li Y, Dai Z. An overview of osteocalcin progress. J Bone Miner Metab. 2016;34(4):367–79.CrossRefGoogle Scholar
  11. 11.
    Villafán-Bernal JR, Sánchez-Enríquez S, Muñoz-Valle JF. Molecular modulation of osteocalcin and its relevance in diabetes (review). Int J Mol Med. 2011;28(3):283–93.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Xu L, Guo H, Li C, Xu J, Fang W, Long X. A time-dependent degeneration manner of condyle in rat CFA-induced inflamed TMJ. Am J Transl Res. 2016;8(2):556–67.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015;21:55–70.CrossRefGoogle Scholar
  14. 14.
    Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone. 2016;96:29–37. pii: S8756-3282(16)30297-6.CrossRefGoogle Scholar
  15. 15.
    Appelman-Dijkstra NM, Papapoulos SE. Sclerostin inhibition in the management of osteoporosis. Calcif Tissue Int. 2016;98(4):370–80.CrossRefGoogle Scholar
  16. 16.
    Jay GD. Characterization of a bovine synovial fluid lubricating factor. I. Chemical, surface activity and lubricating properties. Connect Tissue Res. 1992;28(1-2):71–88.CrossRefGoogle Scholar
  17. 17.
    Jay GD, Britt DE, Cha CJ. Lubricin is a product of megakaryocyte stimulating factor gene expression by human synovial fibroblasts. J Rheumatol. 2000;27(3):594–600.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Alquraini A, Garguilo S, D'Souza G, Zhang LX, Schmidt TA, Jay GD, Elsaid KA. The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther. 2015;17:353.CrossRefGoogle Scholar
  19. 19.
    Lee SY, Yoon BY, Kim JI, Heo YM, Woo YJ, Park SH, Kim HY, Kim SI, Cho ML. Interleukin-17 increases the expression of toll-like receptor 3 via the STAT3 pathway in rheumatoid arthritis fibroblast-like synoviocytes. Immunology. 2014;141(3):353–61.CrossRefGoogle Scholar
  20. 20.
    Kim KW, Cho ML, Oh HJ, Kim HR, Kang CM, Heo YM, Lee SH, Kim HY. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett. 2009;124(1):9–17.CrossRefGoogle Scholar
  21. 21.
    Khakshooy A, Kasar RV, Nachivan M, Quyen Bach Q, Chiappelli F. Increased literacy of the best evidence base optimizes patient-clinician communication in convergent translational healthcare: relevance of patient-centered modalities. Dental Hypotheses. 2015;6:146–50.CrossRefGoogle Scholar
  22. 22.
    Kurowska-Stolarska M, Alivernini S, Ballantine LE, Asquith DL, Millar NL, Gilchrist DS, Reilly J, Ierna M, Fraser AR, Stolarski B, McSharry C, Hueber AJ, Baxter D, Hunter J, Gay S, Liew FY, McInnes IB. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA. 2011;108(27):11193–8.CrossRefGoogle Scholar
  23. 23.
    Brommage R. Genetic approaches to identifying novel osteoporosis drug targets. J Cell Biochem. 2015;116(10):2139–45.CrossRefGoogle Scholar
  24. 24.
    Jing W, Zhang X, Sun W, Hou X, Yao Z, Zhu Y. CRISPR/CAS9-mediated genome editing of miRNA-155 inhibits proinflammatory cytokine production by RAW264.7 cells. Biomed Res Int. 2015;2015:326042.CrossRefGoogle Scholar
  25. 25.
    Barkhordarian A, Demerjian G, Jan A, Sama N, Nguyen M, Du A, Chiappelli F. Stakeholder engagement analysis—a bioethics dilemma in patient-targeted intervention: patients with temporomandibular joint disorders. J Transl Med. 2015;13:15.CrossRefGoogle Scholar
  26. 26.
    Kopp S. Neuroendocrine, immune, and local responses related to temporomandibular disorders. J Orofac Pain. 2001;15(1):9–28.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Chiappelli F, Barkhordarian A, Demerjian G, Bach Q, Kasar V. Cluster randomized stepped wedge blinded controlled trials (CRSWBCT) in comparative effectiveness research (CER)—part I: toward a revision of CONSORT. Transl Med. 2015;5:e128.Google Scholar
  28. 28.
    Chiappelli F, Barkhordarian A, Demerjian G, Bach Q, Kasar V. Cluster randomized stepped wedge blinded controlled trials (CRSWBCT) in comparative effectiveness research (CER) part II: implications for temporomandibular joint disorders (TMD) research. Transl Med. 2015;5:e131.Google Scholar
  29. 29.
    Chiappelli F, Khakshooy A. Individual patient research outcomes for patients with Alzheimer’s disease: the Psychoneuroimmune viewpoint. Bioinformation. 2016;12:263–5.CrossRefGoogle Scholar
  30. 30.
    Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–5.CrossRefGoogle Scholar
  31. 31.
    Chiappelli F, Prolo P. The meta-construct of evidence based dentistry: part I. J Evid Based Dent Pract. 2001;1:159–65.CrossRefGoogle Scholar
  32. 32.
    Chiappelli F, Prolo P. The meta-construct of evidence based dentistry: part II. J Evid Based Dent Pract. 2002;2:1–7.CrossRefGoogle Scholar
  33. 33.
    Barkhordarian A, Ramchandani MH, Dousti M, Kelly-Gleason L, Chiappelli F. Disseminating the best available evidence: new challenges in public reporting of health care. Bioinformation. 2012;8:293–5.CrossRefGoogle Scholar
  34. 34.
    De Almeida Moura J, Carvalho Costa B, Delbone de Faria RM, Figueiredo Soares T, Perlatto Moura E, Chiappelli F. Improving communication skill training in patient centered medical practice for enhancing rational use of laboratory tests: the core of bioinformation for leveraging stakeholder engagement in regulatory science. Bioinformation. 2013;9:718–20.CrossRefGoogle Scholar
  35. 35.
    Barkhordarian A, Hacker B, Chiappelli F. Dissemination of evidence-based standards of care. Bioinformation. 2011;7:315–9.CrossRefGoogle Scholar
  36. 36.
    Chiappelli F, Barkhordarian A, Arora R, Phi L, Giroux A, Uyeda M, Kung K, Ramchandani M. Reliability of quality assessments in research synthesis: securing the highest quality bioinformation for HIT. Bioinformation. 2012;8:691–4.CrossRefGoogle Scholar
  37. 37.
    Obama BH. United States health care reform: progress to date and next steps. JAMA. 2016;316(5):525–32.CrossRefGoogle Scholar
  38. 38.
    Chiappelli F, Khakshooy AM, Bakhordarian A, Kasar VR, Nahcivan M, Nguyen MT, Hwang JM, Martinez Kutschman M, Du A. Global convergent translational science for Neuro-involvement in Ebola viral disease: lessons learned from neuro-AIDS. In: Shapshak P, Sinnott JT, Somboonwit C, Singer E, Levine AJ, Foley BT, Chiappelli F, editors. Global virology II. New York, NY: Springer-US; 2017.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Francesco Chiappelli
    • 1
    • 2
    Email author
  • André Barkhordarian
    • 1
    • 2
  • Eliseo B. SabalJr
    • 3
  • Allen Khakshooy
    • 3
    • 4
  • G. Gary Demerjian
    • 1
    • 2
    • 5
  1. 1.UCLA School of DentistryLos AngelesUSA
  2. 2.Evidence-Based Decisions Practice-Based Research NetworkLos AngelesUSA
  3. 3.Division of Oral Biology and MedicineUCLA School of DentistryLos AngelesUSA
  4. 4.Rappaport Faculty of Medicine, Technion-Israel Institute of TechnologyHaifaIsrael
  5. 5.Center for TMJ & Sleep TherapyGlendoraUSA

Personalised recommendations